In a recent transaction, Paul J. Diaz, the President and CEO of Myriad Genetics Inc. (NASDAQ:MYGN), sold shares of the company's stock. On October 11, 2024, Diaz completed the sale of 15,000 shares at a price of $22.93 per share, totaling $343,950.
The sale was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information. This ensures that they comply with insider trading laws and regulations.
Following the transaction, the CEO still owns a significant number of shares in Myriad Genetics, totaling 962,378. This indicates a continued vested interest in the company's performance and future.
Myriad Genetics, based in Salt Lake City, Utah, specializes in in vitro and in vivo diagnostic substances. The company has been a key player in the field of personalized medicine and genetic testing.
Investors often monitor insider sales as they may provide insights into an executive’s perspective on the company's current valuation and future prospects. However, it is also common for executives to sell shares for personal financial reasons that do not necessarily reflect their outlook on the company’s future performance.
The details of these transactions are publicly disclosed for investors and market observers to ensure transparency and maintain fair trading practices in the securities markets.
In other recent news, Myriad Genetics has seen a flurry of analyst activity. Stephens increased its stock target for the company to $28, pointing to a robust project inventory and a new Floating Storage Regasification Unit expected in 2026. Leerink Partners has also raised its price target to $40, following the company's Investor Day, which outlined key growth drivers and long-term financial goals. However, not all analysts are bullish. JPMorgan (NYSE:JPM) maintained its Underweight rating and a $20 price target, while BofA Securities held an Underperform rating.
Myriad Genetics reported third-quarter revenue figures between $210-212 million, surpassing expectations. The company also reaffirmed its 2024 revenue guidance of $835-845 million. Furthermore, Myriad Genetics announced collaborations with The University of Texas MD Anderson Cancer Center and The University of Rochester Medical Center, focusing on breast cancer molecular residual disease testing research. The company's Precise MRD test is expected to launch commercially in 2026.
In other developments, Myriad Genetics discontinued part of its GeneSight study. Despite this, Wells Fargo (NYSE:WFC) listed Myriad Genetics among its high-conviction ideas for sustained growth into 2025. These are some of the recent developments concerning Myriad Genetics.
InvestingPro Insights
To provide additional context to Paul J. Diaz's recent stock sale, let's examine some key financial metrics and insights from InvestingPro for Myriad Genetics Inc. (NASDAQ:MYGN).
According to InvestingPro data, Myriad Genetics has a market capitalization of $2.19 billion. The company has shown strong revenue growth, with a 14.78% increase over the last twelve months as of Q2 2024, reaching $802.2 million. This growth trend is particularly relevant given the CEO's recent stock transaction, as it suggests the company is expanding its market presence.
An InvestingPro Tip indicates that MYGN's stock has experienced a high return over the last year, with a one-year price total return of 51.08% as of the latest data. This significant appreciation might explain why the CEO chose to sell some shares, possibly to realize gains.
Another InvestingPro Tip notes that while the company operates with a moderate level of debt, it has not been profitable over the last twelve months. This is reflected in the negative operating income of $103.3 million for the same period. However, analysts predict that the company will be profitable this year, which could be a positive sign for investors.
It's worth noting that MYGN's stock price movements are quite volatile, as highlighted by another InvestingPro Tip. This volatility, combined with the recent 12.84% price decline over the past week, may have influenced the timing of the CEO's stock sale.
For readers interested in a more comprehensive analysis, InvestingPro offers 7 additional tips for Myriad Genetics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.